Home Stable Isotopes CS-T-97487

Galanthamine-O-methyl-d3 Hydrobromide

Stable Isotopes CAT No. CS-T-97487
Enquire
Product Detail

Galanthamine-O-methyl-d3 Hydrobromide

Stable Isotopes
Stock Status: Enquire
Live
For Research & Analytical Purposes. Not for Personal use.
Category Stable Isotopes
API Family --
Storage Refer MSDS for complete information.
Hazard Information Refer MSDS for complete information.

Galanthamine-O-methyl-d3 Hydrobromide Product Information

Galanthamine-O-methyl-d3 Hydrobromide is listed under Stable Isotopes. It is associated with and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-97487.

Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.

Technical Data

Product Name
Galanthamine-O-methyl-d3 Hydrobromide
CAS No.
-
CAT No.
CS-T-97487
Molecular Formula
C17H19D3BrNO3
Molecular Weight
371.28
Category
Storage Condition
Refer MSDS for complete information.
IUPAC Name
Galanthamine-O-methyl-d3 Hydrobromide
Hazard Compound
Refer MSDS for complete information.

Description

Overview
"Galanthamine-O-methyl-d3 Hydrobromide is the labeled analogue of Galanthamine Hydrobromide (G188500), a selective acetylcholinesterase inhibitor. A therapeutic agent for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism."
Synonyms
"(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-d3-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide; Galanthamine-d3 Hydrobromide; (-)-Galantamine-d3 Hydrobromide; (-)-Galanthamine-d3 Hydrobromide; Galantamine-d3 Hydrobromide; Galanthamin"
Application Notes
"Galanthamine-O-methyl-d3 Hydrobromide is the labeled analogue of Galanthamine Hydrobromide (G188500), a selective acetylcholinesterase inhibitor. A therapeutic agent for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism."
References
"Friess, S.L., et al.: Toxicol. Appl. Pharmacol., 3, 347 (1961); Bickel, U., et al.: Clin. Pharmacol. Ther., 50, 420 (1991); Harvey, A.L., et al.: Pharmacol. Ther., 68, 113 (1995)"
Downloading MSDS…
Done
Done
RFQ Basket 0
Done
RFQ Basket 0
Quick Enquiry
Tell us what you need
Quote Basket
Selected RFQ Items
Your RFQ basket is empty. Add a product block or copy a guided requirement here.